Navigation Links
Valeant Announces the Completion of the Privatization of Afexa Life Sciences Inc.
Date:12/12/2011

information about Valeant Pharmaceuticals International, Inc. can be found at www.valeant.com.

Forward Looking Information

To the extent any statements made in this document contain information that is not historical, these statements are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended and may be forward-looking information as defined under applicable Canadian securities legislation (collectively, "forward-looking statements").

Forward-looking statements may be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in Valeant's most recent annual or quarterly report filed with the SEC and risks and uncertainties as detailed from time to time in Valeant's filings with the SEC and the Canadian Securities Administrators, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. Valeant undertakes no obligation to update any of these forward-looking statements to reflect the events or circumstances after the date of this press release or to reflect actual outcomes, except as required by applicable securities laws.

(Logo: http://photos.prnewswire.com/prnh/20101025/LA87217LOGO)

Contact Inf
'/>"/>

SOURCE Valeant Pharmaceuticals International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Valeant Pharmaceuticals Receives Approval From FTC in Connection With Acquisition of Ortho Dermatologics and Dermik
2. Valeant Pharmaceuticals to Syndicate Incremental Term Loans
3. Valeant Pharmaceuticals Appoints Howard B. Schiller as Chief Financial Officer
4. Valeant Announces Take-Up of Additional Afexa Shares and Special Meeting of Shareholders of Afexa to Approve Its Privatization
5. Valeant Pharmaceuticals to Announce 2011 Third Quarter Results on November 3, 2011
6. Valeant Pharmaceuticals Announces Approval Of Colesevelam Hydrochloride In Canada
7. Valeant Pharmaceuticals Intends to Raise Offer for Afexa Life Sciences Inc. to $0.85 per Share
8. Valeant Pharmaceuticals to Refinance Senior Secured Credit Facilities
9. Valeant Pharmaceuticals Announces Mailing of Offer and Take-Over Bid Circular to Shareholders of Afexa
10. Valeant Pharmaceuticals to Present at Industry Conferences
11. Valeant Pharmaceuticals Announces Increase to Monetary Limit Under Its Securities Repurchase Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... , Nov. 26, 2014  Avanir Pharmaceuticals, ... the U.S. Food and Drug Administration (FDA) has ... Drug Application (NDA) for AVP-825. AVP-825 is an ... powder delivered intranasally utilizing a novel Breath Powered ... Response letter, and consistent with the preliminary feedback ...
(Date:11/26/2014)... N.Y. , Nov. 26, 2014  BioScrip ® , Inc. ... Smith , President and Chief Executive Officer, will present at the ... , , , Date: , , , Wednesday, ... , 2:50 p.m. EST , , , , Location: , ... About BioScrip, Inc. BioScrip, ...
(Date:11/26/2014)... Nov. 26, 2014  Aridis Pharmaceuticals, Inc., a ... therapies for infectious diseases, announced today the addition ... recognized key opinion leader in the areas of ... board. Founder and Chief Executive Officer, ... Dr. Opal,s extensive experience investigating bacterial toxins and ...
Breaking Medicine Technology:Avanir Pharmaceuticals Receives Complete Response Letter (CRL) from FDA on AVP-825 NDA 2Avanir Pharmaceuticals Receives Complete Response Letter (CRL) from FDA on AVP-825 NDA 3Avanir Pharmaceuticals Receives Complete Response Letter (CRL) from FDA on AVP-825 NDA 4Aridis Pharmaceuticals Appoints Dr. Steven Opal to Scientific Advisory Board 2Aridis Pharmaceuticals Appoints Dr. Steven Opal to Scientific Advisory Board 3
... WIRE)--Apr 19, 2007 - King,Pharmaceuticals, Inc. (NYSE:KG) ... results from the Phase III clinical trial,evaluating ... ALTACE(R),(ramipril) diuretic fixed-dose combination product. The Company ... expects to present the,findings in detail at ...
... AACR Highlight Progress in SuperGen's,Oncology-Focused Pre-Clinical Pipeline, ... SuperGen,Inc. today announced that MP470, its multi-targeted ... critical component of,double- stranded DNA repair in ... of,presentations at the 2007 American Association for ...
Cached Medicine Technology:King Pharmaceuticals Announces Plan to Report Positive Data from,Phase III Clinical Trial Evaluating the Combination of Altace with,Hydrochlorothiazide 2Data Show SuperGen's Multi-Targeted Tyrosine Kinase Inhibitor,Suppresses Critical Double-Stranded DNA Repair Protein, Rad51 2Data Show SuperGen's Multi-Targeted Tyrosine Kinase Inhibitor,Suppresses Critical Double-Stranded DNA Repair Protein, Rad51 3Data Show SuperGen's Multi-Targeted Tyrosine Kinase Inhibitor,Suppresses Critical Double-Stranded DNA Repair Protein, Rad51 4Data Show SuperGen's Multi-Targeted Tyrosine Kinase Inhibitor,Suppresses Critical Double-Stranded DNA Repair Protein, Rad51 5Data Show SuperGen's Multi-Targeted Tyrosine Kinase Inhibitor,Suppresses Critical Double-Stranded DNA Repair Protein, Rad51 6Data Show SuperGen's Multi-Targeted Tyrosine Kinase Inhibitor,Suppresses Critical Double-Stranded DNA Repair Protein, Rad51 7
(Date:11/27/2014)... Blood-borne pathogens raise the risk of spreading diseases, ... place to counter this. However, it doesn’t seem as ... menstrual blood are taken as seriously. , "This ... to handle tampons and menstrual pads while also protecting ... He then created a prototype of the Sani-M, an ...
(Date:11/27/2014)... 2014 "As a nurse I see ... of urinary incontinence," said an inventor from Whiting, N.J. ... specialized accessory to prevent leakage and keep them dry ... urine leakage. This prevents stains on pants, skirts and ... pad ensures that the individual has time to get ...
(Date:11/27/2014)... HealthDay Reporter , WEDNESDAY, Nov. 26, 2014 (HealthDay ... second language, new research suggests. But anyone who tries to ... boost, the small study finds. The brain "becomes ... Li, co-director of the Center for Brain, Behavior and Cognition ... said, that "the brain networks of the more successful learners ...
(Date:11/27/2014)... Dennis Thompson HealthDay Reporter ... experimental Ebola vaccine appears to be safe and produces an ... virus, according to early clinical trial results reported by the ... phase I clinical trial for the vaccine paves the way ... Liberia and Sierra Leone as early as January, said Dr. ...
(Date:11/27/2014)... November 27, 2014 In order to enable ... Sharpes, Fla., designed an easy way to avoid touching a ... He then created a prototype of the patent-pending Toilet Tamer, ... a toilet seat and/or lid in a more sanitary manner. ... spread of germs. Overall, it promotes good hygiene and peace ...
Breaking Medicine News(10 mins):Health News:Some People May Be Pre-Wired to Be Bilingual 2Health News:Some People May Be Pre-Wired to Be Bilingual 3Health News:Early Trial Promising for Ebola Vaccine 2Health News:Early Trial Promising for Ebola Vaccine 3
... infections occuring more often than previously believed, study finds ... drug-resistant staph infections are more common, both in and ... study warns. , Methicillin-resistant Staphylococcus aureus (MRSA) infections are ... among people in hospitals and can result in severe ...
... Even though Americans pick up their,toothbrushes for a ... cleaning of their own. Celebrity Dentist Dr. Bill Dorfman ... survey conducted by the,Philips Sonicare brand shows dirty brushes ... this report from Philips (NYSE: PHG ) at:, ...
... Gentiva Health,Services, Inc. (Nasdaq: GTIV ), the ... today announced that it has,scheduled a conference call and ... ET to discuss operating results for the third quarter ... issue its financial news,release the morning of November 1 ...
... Request Highlights December 2 Annual Wells Fargo Walk of Ages ... ... is,inviting everyone with the name of "Walker" in the United States to either,join ... of,Ages" on December 2 in Reseda. According to official census records there,are 663,233 ...
... Oct. 16 Young Innovations, Inc.,(Nasdaq: YDNT ) ... results with a live and on-demand web cast conference ... Time. A live audio,broadcast of the call will be ... live audio broadcast,will also be available through the Company,s ...
... SYMBOL - BCL.P, VANCOUVER, Oct. 16 ... to announce that it has entered into ... 2007 (the "Arrangement,Agreement") with iCo Therapeutics Inc. ... will constitute Beanstalk,s,"Qualifying Transaction" as a capital ...
Cached Medicine News:Health News:Drug-Resistant Staph a Widespread Threat 2Health News:Drug-Resistant Staph a Widespread Threat 3Health News:Gentiva(R) Health Services Schedules Third Quarter Earnings Call and Web Cast for Thursday, November 1, 2007 2Health News:Gentiva(R) Health Services Schedules Third Quarter Earnings Call and Web Cast for Thursday, November 1, 2007 3Health News:FORGET THE JONESES, This is All About Keeping up With the Walkers as the Los Angeles Jewish Home Sends Out an Invite to Everyone Named 'Walker' in the United States 2Health News:Beanstalk Capital Ltd. enters into arrangement agreement with iCo Therapeutics Inc. 2Health News:Beanstalk Capital Ltd. enters into arrangement agreement with iCo Therapeutics Inc. 3Health News:Beanstalk Capital Ltd. enters into arrangement agreement with iCo Therapeutics Inc. 4Health News:Beanstalk Capital Ltd. enters into arrangement agreement with iCo Therapeutics Inc. 5Health News:Beanstalk Capital Ltd. enters into arrangement agreement with iCo Therapeutics Inc. 6Health News:Beanstalk Capital Ltd. enters into arrangement agreement with iCo Therapeutics Inc. 7Health News:Beanstalk Capital Ltd. enters into arrangement agreement with iCo Therapeutics Inc. 8Health News:Beanstalk Capital Ltd. enters into arrangement agreement with iCo Therapeutics Inc. 9Health News:Beanstalk Capital Ltd. enters into arrangement agreement with iCo Therapeutics Inc. 10
... temporary internal drainage from the ... Supplied sterile in peel-open packages. ... Periodic evaluation is advised; polyurethane, ... not remain indwelling more than ...
... for temporary internal drainage from ... bladder. Supplied sterile in peel-open ... CAUTION: Periodic evaluation is advised; ... must not remain indwelling more ...
... Used for catheter or instrument introduction. ... to be peeled away and removed. ... or instrument to be introduced should ... through the sheath. Supplied sterile in ...
... Used to provide ... or epispadias repair. The ... to partially close during ... urethra while maintaining urethral ...
Medicine Products: